Eyebright Medical Technology (Beijing) Co., Ltd. (688050.SS)
CNY 79.03
(1.18%)
CNY 79.03
(1.18%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 423.87 Million CNY | 24.1% |
| 2022 | 318.52 Million CNY | 40.09% |
| 2021 | 228.18 Million CNY | 61.36% |
| 2020 | 137.7 Million CNY | 46.8% |
| 2019 | 94.04 Million CNY | 134.86% |
| 2018 | 40.79 Million CNY | 404.07% |
| 2017 | 1.73 Million CNY | 70.39% |
| 2016 | 3.49 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 122.59 Million CNY | 59.55% |
| 2024 Q2 | 152.76 Million CNY | 22.41% |
| 2023 Q1 | 90.42 Million CNY | 130.03% |
| 2023 FY | - CNY | 24.1% |
| 2023 Q4 | 72.72 Million CNY | -29.21% |
| 2023 Q3 | 102.73 Million CNY | 7.65% |
| 2023 Q2 | 95.43 Million CNY | 5.54% |
| 2022 FY | - CNY | 40.09% |
| 2022 Q4 | 39.31 Million CNY | -54.6% |
| 2022 Q3 | 86.58 Million CNY | 15.71% |
| 2022 Q2 | 74.83 Million CNY | 1.26% |
| 2022 Q1 | 73.9 Million CNY | 97.15% |
| 2021 Q1 | 39.26 Million CNY | 17.78% |
| 2021 Q3 | 54.45 Million CNY | -14.55% |
| 2021 Q2 | 63.73 Million CNY | 62.32% |
| 2021 Q4 | 37.48 Million CNY | -31.17% |
| 2021 FY | - CNY | 61.36% |
| 2020 Q3 | 33.22 Million CNY | -32.95% |
| 2020 Q1 | 9.19 Million CNY | 113.11% |
| 2020 FY | - CNY | 46.8% |
| 2020 Q4 | 33.33 Million CNY | 0.35% |
| 2020 Q2 | 49.54 Million CNY | 438.94% |
| 2019 Q4 | -70.12 Million CNY | -712.4% |
| 2019 FY | - CNY | 134.86% |
| 2019 Q3 | 11.45 Million CNY | -57.58% |
| 2019 Q2 | 26.99 Million CNY | -1.22% |
| 2019 Q1 | 27.32 Million CNY | 144.41% |
| 2018 Q4 | -61.53 Million CNY | 0.0% |
| 2018 FY | - CNY | 404.07% |
| 2017 FY | - CNY | 70.39% |
| 2016 FY | - CNY | 0.0% |